Brought to you by 
Zeria gets Japanese rights to Vifor's hyperkalemia drug
27 Mar 2018
Executive Summary
Vifor Pharma Group licensed Zeria Pharmaceutical Co. Ltd. exclusive rights to develop and commercialize the hyperkalemia therapy Veltassa (patiromer) in Japan.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Zeria gets Japanese rights to Vifor's hyperkalemia drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice